Retrospective study of late stage use on 2,512 hospitalized patients showing no significant differences in associated mortality for patients receiving any HC
Q during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), HC
Q alone (HR, 1.02 [95% CI, 0.83-1.27]), or HC
Q+AZ (HR, 0.98 [95% CI, 0.75-1.28]). Misclassification is possible due to manual abstraction of EHR data. They observed a change in the prescribing patterns of HC
Q during the study timeframe. Confounding by indication.
death, ↓1.0%, p=0.93